Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234756 | 0.87 | HPGD (0.42) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL4627304 | 0.85 | TSHR (0.49) | ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3 | |
| SCHEMBL289045 | 0.83 | ALDH1A1 (0.55) | UTS2RALDH1A1SMN1; SMN2GABRA1GABRB1 | |
| SCHEMBL5735465 | 0.81 | AAK1 (0.33) | UTS2RALDH1A1SMN1; SMN2GABRA1GABRB1 | |
| SCHEMBL277358 | 0.79 | AAK1 (0.43) | UTS2RSMN1; SMN2GABRA1GABRA3GABRB2 | |
| SCHEMBL231518 | 0.78 | SERPINE1 (0.41) | ALDH1A1SMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL6911640 | 0.77 | TSHR (0.54) | ALDH1A1SMN1; SMN2LMNAATMHPGD | |
| SCHEMBL187447 | 0.76 | NR4A2 (0.53) | UTS2RALDH1A1SMN1; SMN2RAB9AFLT1 | |
| SCHEMBL30752935 | 0.76 | NR4A2 (0.53) | UTS2RALDH1A1SMN1; SMN2RAB9AFLT1 | |
| SCHEMBL3950165 | 0.76 | ALDH1A1 (0.54) | ALDH1A1LMNARAB9AAAK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366036-B1 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6855512-B2 | Methods for identifying inhibitors of cytochrome P450RAI | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6713647-B2 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1366036-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6603019-B2 | Phenylacetic or heteroarylacetic acid derivatives, retinoic acid inducible enzyme, used to treat diseases responsive to retinoids | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1322631-A2 | METHODS OF PROVIDING AND USING COMPOUNDS ( RETINOIDS ) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6531599-B2 | RAI=retinoic acid inducible; for example, 4-((8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro(2H-1-benzopyran-2,1' -cyclopropane)-6-yl) ethynyl)-2-fluoro-benzoic acid; use treating diseases responsive to retinoids | ALLERGAN SALES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6380256-B1 | FOR THERAPY OF DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6369261-B1 | CYCLOPROPYLBENZENE DERIVATIVE OF ACIDS OR ESTERS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6369225-B1 | ENZYME INHIBITORS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6303785-B1 | SUBSTITUTED N-CYCLOPROPYLTETRAHYDROISOQUINOLINES | ALLERGAN SALES, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6291677-B1 | FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES AND KERATINIZATION AND HYPERPROLIFERATIVE DISORDERS OF SKIN | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | UTS2R 1738/4885ALDH1A1 72/4885SMN1; SMN2 3067/4885 |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | UTS2R 2054/4885ALDH1A1 69/4885SMN1; SMN2 3157/4885 |
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | UTS2R 2180/4885ALDH1A1 46/4885SMN1; SMN2 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.